Haddock Michael G
Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
Radiat Oncol. 2017 Jan 11;12(1):11. doi: 10.1186/s13014-016-0752-1.
Although there have been significant advances in the adjuvant therapy of colorectal cancer, results for patients have historically been poor when complete resection is unlikely or not possible. Similarly, locally recurrent colorectal cancer patients often experience significant tumor related morbidity and disease control and long term survival have historically been poor with standard therapies. Intraoperative radiation therapy (IORT) has been proposed as a possible tool for dose escalation in patients with locally advanced colorectal cancer.For patients with locally advanced primary or recurrent colon cancer, the absence of prospective controlled trials limits the ability to draw definitive conclusions in completely resected patients. In subtotally resected patients, the available evidence is consistent with marked improvements in disease control and survival compared to historical controls. For patients with locally advanced primary or recurrent rectal cancer, a relatively large body of evidence suggests improved disease control and survival, especially in subtotally resected patients, with the addition of IORT to moderate dose external beam radiation (EBRT) and chemotherapy. The most important prognostic factor in nearly all series is the completeness of surgical resection. Many previously irradiated patients may be carefully re-treated with radiation and IORT in addition to chemotherapy resulting in long term survival in more than 25% of patients. Peripheral nerve is dose limiting for IORT and patients receiving 15 Gy or more are at higher risk.IORT is a useful tool when dose escalation beyond EBRT tolerance limits is required for acceptable local control in patients with locally advanced primary or recurrent colorectal cancer. Previously irradiated patients should not be excluded from treatment consideration.
尽管结直肠癌的辅助治疗已取得显著进展,但对于那些不太可能或无法进行完全切除的患者,其治疗效果历来不佳。同样,局部复发性结直肠癌患者通常会经历与肿瘤相关的严重发病率,而且传统疗法在疾病控制和长期生存方面历来效果不佳。术中放射治疗(IORT)已被提议作为局部晚期结直肠癌患者增加剂量的一种可能手段。对于局部晚期原发性或复发性结肠癌患者,由于缺乏前瞻性对照试验,限制了我们对完全切除患者得出明确结论的能力。在次全切除的患者中,现有证据表明与历史对照相比,疾病控制和生存率有显著改善。对于局部晚期原发性或复发性直肠癌患者,相对大量的证据表明,在中等剂量外照射(EBRT)和化疗基础上加用IORT可改善疾病控制和生存率,尤其是在次全切除的患者中。几乎所有系列中最重要的预后因素是手术切除的完整性。许多先前接受过放疗的患者除化疗外,可谨慎地再次接受放疗和IORT,超过25%的患者可实现长期生存。周围神经是IORT的剂量限制因素,接受15 Gy或更高剂量的患者风险更高。对于局部晚期原发性或复发性结直肠癌患者,当需要超过EBRT耐受极限增加剂量以实现可接受的局部控制时,IORT是一种有用的手段。先前接受过放疗的患者不应被排除在治疗考虑之外。